Cue Biopharma(CUE) - 2025 Q4 - Annual Results

Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights BOSTON, Mass., March 16, 2026-- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today reported fourth quarter and full year 2025 financial results. "During the fourth quarter and throughout the full year 2025, the C ...